Thiazolinedione treatment in PCOS-an update

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Polycystic ovary syndrome (PCOS) is characterised by anovulation, hyperandrogenism, and polycystic ovaries. Fifty percent of patients fulfil the criteria for the metabolic syndrome. The pathogenesis of PCOS may be looked as a vicious cycle involving hyperandrogenemia, central obesity, and insulin resistance and medical treatment should aim at breaking this cycle. Lifestyle intervention, oral contraceptives, and insulin sensitises such as metformin are the most commonly used treatment modalities. The thiazolidinediones rosiglitazone and pioglitazone were recently applied as insulin sensitising treatment in patients with PCOS. Thiazolidinediones activate the transcription of genes that affect glucose and lipid metabolism mediating decreased free fatty acid levels and decreased visceral fat mass. In the present article, we give an overview of the diverse effects of glitazone treatment in patients with PCOS. We review the studies comparing glitazone versus metformin and oral contraceptive treatment and recommend which patients should be treated with glitazones in daily praxis.
OriginalsprogEngelsk
TidsskriftGynecological Endocrinology
Vol/bind26
Udgave nummer11
Sider (fra-til)791-803
Antal sider13
ISSN0951-3590
DOI
StatusUdgivet - 1. nov. 2010

Fingeraftryk

Thiazolidinediones
Polycystic Ovary Syndrome
rosiglitazone
pioglitazone
Oral Contraceptives
Insulin
Hyperandrogenism
Intra-Abdominal Fat
Abdominal Obesity
Lipid Metabolism
Nonesterified Fatty Acids
Insulin Resistance
Ovary

Citer dette

@article{d94a992db3364848a859e4bbd3ba8da8,
title = "Thiazolinedione treatment in PCOS-an update",
abstract = "Polycystic ovary syndrome (PCOS) is characterised by anovulation, hyperandrogenism, and polycystic ovaries. Fifty percent of patients fulfil the criteria for the metabolic syndrome. The pathogenesis of PCOS may be looked as a vicious cycle involving hyperandrogenemia, central obesity, and insulin resistance and medical treatment should aim at breaking this cycle. Lifestyle intervention, oral contraceptives, and insulin sensitises such as metformin are the most commonly used treatment modalities. The thiazolidinediones rosiglitazone and pioglitazone were recently applied as insulin sensitising treatment in patients with PCOS. Thiazolidinediones activate the transcription of genes that affect glucose and lipid metabolism mediating decreased free fatty acid levels and decreased visceral fat mass. In the present article, we give an overview of the diverse effects of glitazone treatment in patients with PCOS. We review the studies comparing glitazone versus metformin and oral contraceptive treatment and recommend which patients should be treated with glitazones in daily praxis.",
author = "Dorte Glintborg and Marianne Andersen",
year = "2010",
month = "11",
day = "1",
doi = "10.3109/09513590.2010.491572",
language = "English",
volume = "26",
pages = "791--803",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Taylor & Francis",
number = "11",

}

Thiazolinedione treatment in PCOS-an update. / Glintborg, Dorte; Andersen, Marianne.

I: Gynecological Endocrinology, Bind 26, Nr. 11, 01.11.2010, s. 791-803.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Thiazolinedione treatment in PCOS-an update

AU - Glintborg, Dorte

AU - Andersen, Marianne

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Polycystic ovary syndrome (PCOS) is characterised by anovulation, hyperandrogenism, and polycystic ovaries. Fifty percent of patients fulfil the criteria for the metabolic syndrome. The pathogenesis of PCOS may be looked as a vicious cycle involving hyperandrogenemia, central obesity, and insulin resistance and medical treatment should aim at breaking this cycle. Lifestyle intervention, oral contraceptives, and insulin sensitises such as metformin are the most commonly used treatment modalities. The thiazolidinediones rosiglitazone and pioglitazone were recently applied as insulin sensitising treatment in patients with PCOS. Thiazolidinediones activate the transcription of genes that affect glucose and lipid metabolism mediating decreased free fatty acid levels and decreased visceral fat mass. In the present article, we give an overview of the diverse effects of glitazone treatment in patients with PCOS. We review the studies comparing glitazone versus metformin and oral contraceptive treatment and recommend which patients should be treated with glitazones in daily praxis.

AB - Polycystic ovary syndrome (PCOS) is characterised by anovulation, hyperandrogenism, and polycystic ovaries. Fifty percent of patients fulfil the criteria for the metabolic syndrome. The pathogenesis of PCOS may be looked as a vicious cycle involving hyperandrogenemia, central obesity, and insulin resistance and medical treatment should aim at breaking this cycle. Lifestyle intervention, oral contraceptives, and insulin sensitises such as metformin are the most commonly used treatment modalities. The thiazolidinediones rosiglitazone and pioglitazone were recently applied as insulin sensitising treatment in patients with PCOS. Thiazolidinediones activate the transcription of genes that affect glucose and lipid metabolism mediating decreased free fatty acid levels and decreased visceral fat mass. In the present article, we give an overview of the diverse effects of glitazone treatment in patients with PCOS. We review the studies comparing glitazone versus metformin and oral contraceptive treatment and recommend which patients should be treated with glitazones in daily praxis.

U2 - 10.3109/09513590.2010.491572

DO - 10.3109/09513590.2010.491572

M3 - Journal article

C2 - 20528570

VL - 26

SP - 791

EP - 803

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 11

ER -